Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Other Non-Current Liabilities (2022 - 2025)

Serina Therapeutics (SER) has disclosed Other Non-Current Liabilities for 4 consecutive years, with $3.5 million as the latest value for Q2 2025.

  • Quarterly Other Non-Current Liabilities fell 73.54% to $3.5 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Jun 2025, down 73.54% year-over-year, with the annual reading at $3.6 million for FY2024, N/A changed from the prior year.
  • Other Non-Current Liabilities hit $3.5 million in Q2 2025 for Serina Therapeutics, up from $2.6 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $24.1 million in Q1 2024 to a low of $180000.0 in Q4 2022.
  • Historically, Other Non-Current Liabilities has averaged $5.3 million across 4 years, with a median of $2.6 million in 2025.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 6839.19% in 2024 and later plummeted 89.23% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $180000.0 in 2022, then surged by 92.78% to $347000.0 in 2023, then soared by 932.28% to $3.6 million in 2024, then dropped by 0.92% to $3.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for SER at $3.5 million in Q2 2025, $2.6 million in Q1 2025, and $3.6 million in Q4 2024.